

# Lasmiditan is an effective acute treatment for migraine

## A phase 3 randomized study

Bernice Kuca, BA, MS, Stephen D. Silberstein, MD, Linda Wietecha, BSN, MS, et al., on behalf of the COL MIG-301 Study Group

Cite as: *Neurology*® 2018;91:e2222-e2232. doi:10.1212/WNL.0000000000006641

### Correspondence

Ms. Wietecha  
wietecha\_linda\_a@lilly.com

### Study objective

To assess the efficacy of lasmiditan in acute migraine.

### Summary results

Lasmiditan is an efficacious treatment for acute migraine.

### Classification of evidence

Class I.

### What is known and what this paper adds

Triptans are common treatments for migraine but are contraindicated in patients with certain cardiovascular conditions. This study shows that lasmiditan is an efficacious antimigraine therapy that is safe for patients with multiple cardiovascular risk factors.

### Participants and setting

This study randomized 2,231 patients who experienced 3–8 migraine attacks per month, had experienced disabling migraine for  $\geq 12$  months, and had Migraine Disability Assessment total scores  $\geq 11$ . This study was conducted between April 27, 2015, and August 12, 2016, through 99 US centers.

### Design, size, and duration

This double-blind, phase 3 trial used a central randomization process to assign patients to groups receiving lasmiditan at 200 mg, lasmiditan at 100 mg, or placebo. Participants were instructed to take the issued medication within 4 hours of the onset of the next moderate-to-severe migraine and to subsequently record pain intensities with an electronic diary.

### Primary outcome measures

The primary outcome was freedom from headache pain 2 hours after dosing.

### Main results and the role of chance

The issued tablets were used by 1,856 participants (83.2%). Compared to placebo, lasmiditan was associated with greater likelihoods of freedom from headache pain 2 hours after dosing at both the 200-mg and 100-mg doses ( $p < 0.001$  for both).

**Table** Efficacy of lasmiditan at providing pain relief

Treatment group	Odds ratio (95% confidence interval) relative to placebo group for freedom from headache pain at 2 h
Lasmiditan 200 mg	2.6 (2.0–3.6)
Lasmiditan 100 mg	2.2 (1.6–3.0)

### Harms

The reported adverse events were mostly mild or moderate in severity.

### Bias, confounding, and other reasons for caution

The pain-freedom response rate for the placebo group was unusually high.

### Generalizability to other populations

The fact that 77.9% of the analyzed participants had cardiovascular risk factors other than migraine favors the generalizability of the results.

### Study funding/potential competing interests

This study was funded by CoLucid Pharmaceuticals, an Eli Lilly subsidiary. Some authors report being employed by CoLucid or Eli Lilly; owning stock in healthcare companies, including CoLucid and Eli Lilly; receiving consultancy work, advisory board appointments, and honoraria from scholarly societies, and healthcare companies, including Eli Lilly; being formerly employed by IQVIA, which received contracts from CoLucid; receiving research support from the NIH and foundations; serving on editorial boards; and receiving publication royalties. Go to [Neurology.org/N](http://Neurology.org/N) for full disclosures.

### Trial registration number

NCT02439320 on ClinicalTrials.gov.

*A draft of the short-form article was written by M. Dalefield, a writer with Editage, a division of Cactus Communications. The authors of the full-length article and the journal editors edited and approved the final version.*

# Neurology<sup>®</sup>

## Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study

Bernice Kuca, Stephen D. Silberstein, Linda Wietecha, et al.

*Neurology* 2018;91:e2222-e2232 Published Online before print November 16, 2018

DOI 10.1212/WNL.0000000000006641

### This information is current as of November 16, 2018

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://n.neurology.org/content/91/24/e2222.full">http://n.neurology.org/content/91/24/e2222.full</a>
<b>References</b>	This article cites 22 articles, 3 of which you can access for free at: <a href="http://n.neurology.org/content/91/24/e2222.full#ref-list-1">http://n.neurology.org/content/91/24/e2222.full#ref-list-1</a>
<b>Citations</b>	This article has been cited by 1 HighWire-hosted articles: <a href="http://n.neurology.org/content/91/24/e2222.full##otherarticles">http://n.neurology.org/content/91/24/e2222.full##otherarticles</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>Class I</b> <a href="http://n.neurology.org/cgi/collection/class_1">http://n.neurology.org/cgi/collection/class_1</a> <b>Clinical trials Randomized controlled (CONSORT agreement)</b> <a href="http://n.neurology.org/cgi/collection/clinical_trials_randomized_controlled_consort_agreement">http://n.neurology.org/cgi/collection/clinical_trials_randomized_controlled_consort_agreement</a> <b>Migraine</b> <a href="http://n.neurology.org/cgi/collection/migraine">http://n.neurology.org/cgi/collection/migraine</a> <b>Patient safety</b> <a href="http://n.neurology.org/cgi/collection/patient__safety">http://n.neurology.org/cgi/collection/patient__safety</a> <b>Quality of life</b> <a href="http://n.neurology.org/cgi/collection/quality_of_life">http://n.neurology.org/cgi/collection/quality_of_life</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

